Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab pediatric NMOSD PK/PD and safety study
2023-510007-22-00Phase 2Authorised
- Sponsor
- Horizon Therapeutics
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Horizon Therapeutics. Primary endpoints: Pharmacokinetic parameters, CD20-positive B-cell counts and 1 more. Planned start May 2024; status: authorised.
02
Drugs
inebilizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on 2023-510007-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510007-22-00.